Blood tests and scans to measure muscle loss in liver cancer
Part of Brain & nervous system, Cancer, Digestive system clinical trials.
This study looks at whether measuring certain proteins in your blood (myokines) can help detect muscle loss (sarcopenia) in people with liver cancer, and compares these blood tests to special CT scans. If you're newly diagnosed with liver cancer and have a CT scan already, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with liver cancer (hepatocellular carcinoma).
- You have a CT scan of your belly and pelvis taken before starting any treatment.
- You do not have any other type of active cancer besides liver cancer.
- You do not have an HIV infection that is not well controlled by medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a simple calf measurement with a body scan (X-ray–based scan) to help diagnose sarcopenia, which means age-related loss of muscle strength. It may help your care team decide on the best way to recognize muscle loss early during hospitalization and follow-up.
This study uses ultrasound to measure muscle mass in people with cirrhosis. It aims to understand muscle changes and their link to health outcomes.
This study uses a computer program to look at CT scans of your abdomen to see if muscle loss (sarcopenia) can help predict the course of your liver cirrhosis. The goal is to build a better model to understand how your disease might progress.
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
This study looks at whether doctors can spot “low muscle” (sarcopenia) in everyday clinic care for people with ovarian or endometrial cancer who are planning to start chemotherapy. It may help your care team identify muscle loss early and potentially support better treatment planning.
This study looks at how muscle loss (sarcopenia) might affect side effects from cancer treatments. If you are starting a new cancer treatment, a CT scan before treatment can help doctors predict your risk of side effects.
Hear when a new Sarcopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.